Comite Entreprise Paul Papin

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Cervical cancer1 trial
• Childhood cancers1 trial
• Endometrial cancer1 trial
• Lung cancer1 trial
• Metastatic breast cancer1 trial

Phase

• Phase 34 trials
• Phase 21 trial

Status

• Completed2 trials
• Recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• ARCAGY/ GINECO GROUP1 trial
• Gustave Roussy, Cancer Campus, Grand Paris1 trial
• Institut Gustave Roussy1 trial
• Merck Sharp & Dohme LLC1 trial
• Relay Therapeutics, Inc.1 trial

Running trials

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source

• Recruiting

  Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

  NCT05476939· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Active, not recruiting

  Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

  NCT05201547· Phase 3· ARCAGY/ GINECO GROUP· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting
• Metastatic breast cancer1 recruiting

Closed trials

• Completed

  Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

  NCT03976375· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer

  2024-515533-15-00· Phase 2· Institut Gustave Roussy· Source